Brokerages Set Kura Oncology, Inc. (NASDAQ:KURA) Price Target at $29.86

Kura Oncology, Inc. (NASDAQ:KURA) has received a consensus recommendation of “Buy” from the ten brokerages that are presently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a hold recommendation, eight have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $29.86.

Several research analysts have recently commented on KURA shares. Stifel Nicolaus lowered Kura Oncology from a “buy” rating to a “hold” rating and reduced their price target for the stock from $26.00 to $19.00 in a report on Monday, October 14th. Wedbush reaffirmed an “outperform” rating and set a $37.00 target price on shares of Kura Oncology in a research note on Monday, November 4th. StockNews.com cut shares of Kura Oncology from a “hold” rating to a “sell” rating in a research note on Wednesday, November 20th. Bank of America reduced their price target on shares of Kura Oncology from $36.00 to $29.00 and set a “buy” rating on the stock in a research report on Friday, November 22nd. Finally, HC Wainwright increased their price objective on Kura Oncology from $32.00 to $37.00 and gave the stock a “buy” rating in a research report on Thursday, November 21st.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. Suvretta Capital Management LLC lifted its stake in Kura Oncology by 8.2% during the 3rd quarter. Suvretta Capital Management LLC now owns 7,652,782 shares of the company’s stock worth $149,535,000 after acquiring an additional 583,155 shares in the last quarter. Armistice Capital LLC increased its stake in Kura Oncology by 14.7% during the second quarter. Armistice Capital LLC now owns 2,350,000 shares of the company’s stock worth $48,386,000 after purchasing an additional 302,000 shares during the period. Geode Capital Management LLC boosted its stake in shares of Kura Oncology by 2.4% in the third quarter. Geode Capital Management LLC now owns 1,780,509 shares of the company’s stock valued at $34,798,000 after purchasing an additional 41,535 shares during the period. Franklin Resources Inc. boosted its stake in shares of Kura Oncology by 1.5% in the third quarter. Franklin Resources Inc. now owns 1,588,401 shares of the company’s stock valued at $28,687,000 after purchasing an additional 23,113 shares during the period. Finally, Candriam S.C.A. grew its holdings in shares of Kura Oncology by 39.2% in the second quarter. Candriam S.C.A. now owns 906,482 shares of the company’s stock valued at $18,664,000 after purchasing an additional 255,065 shares in the last quarter.

Kura Oncology Stock Performance

Shares of Kura Oncology stock opened at $8.73 on Monday. The business’s 50 day moving average price is $12.48 and its 200 day moving average price is $17.27. The company has a market cap of $678.88 million, a price-to-earnings ratio of -3.70 and a beta of 0.81. The company has a debt-to-equity ratio of 0.02, a quick ratio of 11.47 and a current ratio of 11.47. Kura Oncology has a one year low of $8.42 and a one year high of $24.17.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.